JP6821054B2 - シリコーン樹脂組成物、その製造方法及びそれを含む瘢痕治療剤 - Google Patents
シリコーン樹脂組成物、その製造方法及びそれを含む瘢痕治療剤 Download PDFInfo
- Publication number
- JP6821054B2 JP6821054B2 JP2019554461A JP2019554461A JP6821054B2 JP 6821054 B2 JP6821054 B2 JP 6821054B2 JP 2019554461 A JP2019554461 A JP 2019554461A JP 2019554461 A JP2019554461 A JP 2019554461A JP 6821054 B2 JP6821054 B2 JP 6821054B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- silicone
- silicone resin
- resin composition
- cst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002050 silicone resin Polymers 0.000 title claims description 82
- 231100000241 scar Toxicity 0.000 title claims description 74
- 239000011342 resin composition Substances 0.000 title claims description 43
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 229920001296 polysiloxane Polymers 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 41
- 239000012530 fluid Substances 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 230000003078 antioxidant effect Effects 0.000 claims description 34
- 239000003995 emulsifying agent Substances 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 27
- 239000003963 antioxidant agent Substances 0.000 claims description 23
- -1 cyclic siloxane Chemical class 0.000 claims description 23
- 230000000475 sunscreen effect Effects 0.000 claims description 22
- 239000000516 sunscreening agent Substances 0.000 claims description 22
- 239000012190 activator Substances 0.000 claims description 19
- 239000003755 preservative agent Substances 0.000 claims description 19
- 230000002335 preservative effect Effects 0.000 claims description 19
- 229940072113 onion extract Drugs 0.000 claims description 16
- 239000001993 wax Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 11
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 10
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 9
- 229920002379 silicone rubber Polymers 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol group Chemical group C(CCCCCCCCCCCCCCC)O BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000004006 olive oil Substances 0.000 claims description 6
- 235000008390 olive oil Nutrition 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 claims description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 claims description 3
- 229940113094 isopropylparaben Drugs 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 2
- GLJADRYELJNXDG-UHFFFAOYSA-N 2-oxopyrrolidine-1-carboxylic acid;zinc Chemical compound [Zn].OC(=O)N1CCCC1=O GLJADRYELJNXDG-UHFFFAOYSA-N 0.000 claims description 2
- 244000291564 Allium cepa Species 0.000 claims description 2
- 235000005255 Allium cepa Nutrition 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229940108925 copper gluconate Drugs 0.000 claims description 2
- JNCPYYJHZPIWKQ-UHFFFAOYSA-N copper;2-oxopyrrolidine-1-carboxylic acid Chemical compound [Cu].OC(=O)N1CCCC1=O JNCPYYJHZPIWKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical group O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 229950004864 olamine Drugs 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229940058349 sodium levulinate Drugs 0.000 claims description 2
- RDKYCKDVIYTSAJ-UHFFFAOYSA-M sodium;4-oxopentanoate Chemical compound [Na+].CC(=O)CCC([O-])=O RDKYCKDVIYTSAJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- 229940043810 zinc pyrithione Drugs 0.000 claims description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 claims 1
- GZYFIMLSHBLMKF-REOHCLBHSA-N L-Albizziine Chemical compound OC(=O)[C@@H](N)CNC(N)=O GZYFIMLSHBLMKF-REOHCLBHSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 claims 1
- 229960005265 selenium sulfide Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 description 20
- 230000037387 scars Effects 0.000 description 20
- 235000006708 antioxidants Nutrition 0.000 description 17
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 16
- 230000002265 prevention Effects 0.000 description 16
- 206010015150 Erythema Diseases 0.000 description 13
- 231100000321 erythema Toxicity 0.000 description 13
- 230000019612 pigmentation Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 229920006268 silicone film Polymers 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 229940008099 dimethicone Drugs 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical group [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 8
- 229960000458 allantoin Drugs 0.000 description 8
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 7
- 241000234282 Allium Species 0.000 description 7
- 229920001971 elastomer Polymers 0.000 description 7
- 239000000806 elastomer Substances 0.000 description 7
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 229920006037 cross link polymer Polymers 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000037390 scarring Effects 0.000 description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 3
- 150000000996 L-ascorbic acids Chemical class 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006750 UV protection Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 229960001679 octinoxate Drugs 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000004728 ear cartilage Anatomy 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CFLAHQSWDKNWPW-UHFFFAOYSA-N 3-(benzyloxy)-3-oxopropanoic acid Chemical class OC(=O)CC(=O)OCC1=CC=CC=C1 CFLAHQSWDKNWPW-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 1
- DWKSHXDVQRZSII-SUMWQHHRSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DWKSHXDVQRZSII-SUMWQHHRSA-N 0.000 description 1
- MSKSZMDNKAEBSG-HNAYVOBHSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O MSKSZMDNKAEBSG-HNAYVOBHSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 150000001565 benzotriazoles Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 150000002398 hexadecan-1-ols Chemical class 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
1−1)ST−Elastomer 10
1−2)TI−3021
2−1)T−7021(400〜1000cst):
3−1)TI−2021((2〜4cst)肌触り改善のために使用)
3−2)TI−1050(粘度範囲が多様であり、使用する製品は、95,000〜105,000cst製であって、粘度調節のために使用する)
3−3)Q7−9120(11,875〜13,125cst)
4−1)ST−Cyclomethicone 5−NF
シリコーン樹脂混合物(Q7−9120:TI−3021:TI−1050:Elastomer 10:TI−7021:5−NF=1:6:2:8:3:80の重量比)64.5gを70℃ で加熱して攪拌する。ビーズワックス25gと乳化剤としてのセチルアルコール7gを70℃で攪拌して添加した後、完全に混ざると、温度を55℃に下げてタマネギ抽出物2g、アスコルビルテトライソパルミテート0.5g及び保存剤としての1,2−ヘキサンジオール1gを入れる。完全に冷える前に容器に入れる。
シリコーン樹脂混合物(TI−1050:TI−2021:TI−3021:TI−7021:Elastomer 10=10:30:20:10:30の重量比)20gにシリコーン乳化剤(Dow corning ES−5300、粘度1800mm2/s)4gとオリーブ油脂肪酸ソルビタン7gを仕込み、65℃で加熱して攪拌する。他の反応器にアラントイン0.5g、EDTAジナトリウム0.05g及び精製水64.45gを仕込み、65℃で加熱して攪拌する。65℃でシリコーン樹脂入りの反応器に精製水入りの反応器の内容物をゆっくりと注ぎながら撹拌する。相が完全に混ざると、加熱を停止し、50℃でタマネギ抽出物2g、酢酸トコフェリル1g、保存剤としての1,2−ヘキサンジオール1gを入れる。完全に冷えるまで撹拌し続ける。
シリコーン樹脂混合物(TI−1050:TI−2021:TI−3021:TI−7021:Elastomer 10=10:30:20:10:30の重量比)20gに、酸化亜鉛10g、オクチノキサート5g、シリコーン乳化剤(Dow corning ES−5300、粘度1800mm2/s)4g、オーリブ油脂肪酸ソルビタン5gを仕込み、65℃で加熱して攪拌する。他の反応器にアラントイン0.5g、EDTAジナトリウム0.05g及び精製水51.45gを仕込み、65℃で加熱して攪拌する。65℃でシリコーン樹脂入りの反応器に精製水入りの反応器の内容物をゆっくりと注ぎながら撹拌する。相が完全に混ざると、加熱を停止し、50℃でタマネギ抽出物2g、酢酸トコフェリル1g、保存剤としての1,2−ヘキサンジオール1gを入れる。完全に冷えるまで撹拌し続ける。
シリコーン樹脂混合物(TI−1050:TI−2021:TI−3021:TI−7021:Elastomer 10=10:30:20:10:30の重量比)20gにシリコーン乳化剤(Dow corning ES−5300、粘度1800mm2/s)4gとオリーブ油脂肪酸ソルビタン7gを仕込み、65℃で加熱して攪拌する。他の反応器にベラパミル0.1g、アラントイン0.5g、EDTAジナトリウム0.05g及び精製水64.35gを仕込み、65℃で加熱して攪拌する。65℃でシリコーン樹脂入りの反応器に精製水入りの反応器の内容物をゆっくりと注ぎながら撹拌する。相が完全に混ざると、加熱を停止し、50℃でタマネギ抽出物2g、酢酸トコフェリル1g、保存剤としての1,2−ヘキサンジオール1gを入れる。完全に冷えるまで撹拌し続ける。
シリコーン樹脂混合物(TI−1050:TI−2021:TI−3021:TI−7021:Elastomer 10:5−NF=5:30:25:10:25:5の重量比)20gにシリコーン乳化剤(Dow corning ES−5300、粘度1800mm2/s)4gとオリーブ油脂肪酸ソルビタン7gを仕込み、65℃で加熱して攪拌する。他の反応器にベラパミル0.1g、アラントイン0.5g、EDTAジナトリウム0.05g及び精製水64.35gを仕込み、65℃で加熱して攪拌する。65℃でシリコーン樹脂入りの反応器に精製水入りの反応器の内容物をゆっくりと注ぎながら撹拌する。相が完全に混ざると、加熱を停止し、50℃でタマネギ抽出物2g、酢酸トコフェリル1g、保存剤としての1,2−ヘキサンジオール1gを入れる。完全に冷えるまで撹拌し続ける。
シリコーン樹脂混合物(Q7−9120:TI−1050:TI−3021:TI−7021:Elastomer 10=1:6:13:5:75の重量比)40gにシリコーン乳化剤(Dow corning Emulsifier 10、HLB ratio2.2%、粘度1100〜3500cpsまたはcst)4gを仕込み、常温で撹拌する。他の反応器にアラントイン0.5g、EDTAジナトリウム0.05g及び精製水55.45gを仕込み、60℃で加熱して攪拌する。精製水入りの反応器を完全に冷やした後、シリコーン樹脂入りの反応器に内容物をゆっくりと注ぎながら撹拌する。相が完全に混ざると、ホモジナイザーを用いて高速攪拌を行う。
Kelo−cote Topical Gel(Formulated Solution LLC製)、Kelo−cote Solaire(Formulated Solutions LLC製)、Dermatix Ultra gel(Toshiki International Singapore Pte Ltd.製)及びBentlax gel(太極製薬製)を比較例1〜4としてそれぞれ使用した。
実施例4及び5で製造されたシリコーン樹脂組成物及び比較例1〜4の瘢痕治療剤の特性を次の方法で測定し、その結果を下記表1及び図2に示した。
*紫外線カット性能(SPF):ISO 2444に基づいて人体パッチテストで測定した。
*べたつき程度:試料を皮膚に塗ったときの肌触りを基準に測定した。べたつきがない場合は+++、普通の場合は++、非常にべたつく場合は+でそれぞれ表示した。
Postoperative 3 weeks術後3週
Scar formation瘢痕形成
Treat scar repair product瘢痕修復製品の処置
図2
実施例 1
Masson's trichrome stainingマッソントリクローム染色
Control(untreated)対照群(未処理)
EP: epitheliumEP:上皮、
DE: dermisDE:真皮、
CA: ear cartilage CA:耳軟骨
Yellow arrow: disorganized collagen 黄色矢印:異常なコラーゲン
Red Arrow: normal pattern collagen 赤色矢印:正常なコラーゲン
Claims (16)
- a)シリコーン樹脂15〜70重量%、b)ワックス1〜25重量%、c)乳化剤2〜8重量%、d)薬物0.5〜2重量%、e)活性化剤1〜5重量%、f)日焼け止め剤0〜30重量%、g)酸化防止剤0〜5重量%、h)水0〜80重量%、及びi)保存剤0.1〜5重量%を含み、
前記a)シリコーン樹脂が、シリコーン樹脂の合計100重量%に対して、シリコーンエラストマー10〜50重量%、フィルム形成剤2〜10重量%、シリコーン流体2〜10重量%及び環状シロキサン0〜80重量%の混合物であり、
前記フィルム形成剤は、ASTM D445、IP71に基づいて、ガラス毛細管粘度計であるウベローデ(フィッシャーサイエンティフィックカンパニー製)を用いて測定した25℃での粘度が400〜1000cstであり、
前記シリコーン流体は、
粘度1〜20cstのシリコーン流体(1)と、粘度80,000〜120,000cstのシリコーン流体(3)との混合物であり、前記シリコーン流体(1)と前記シリコーン流体(3)の重量比は、1:0.15〜0.4であり、または
粘度10,000〜15,000cstのシリコーン流体(2)と前記粘度80,000〜120,000cstのシリコーン流体(3)との混合物であり、前記シリコーン流体(2)と前記シリコーン流体(3)の重量比は、1:1.5〜2.5であり、
前記b)ワックスが、ビーズワックスまたはオリーブ油脂肪酸ソルビタンであり、
前記c)乳化剤が、セチルアルコールまたは粘度1,600〜2,000cstのシリコーン乳化剤であることを特徴とするシリコーン樹脂組成物。 - 前記d)薬物が、抗酸化剤、消炎剤及びカルシウムチャネル遮断剤よりなる群から選択された1種以上であることを特徴とする請求項1に記載のシリコーン樹脂組成物。
- 前記e)活性化剤が、ビタミン誘導体及びタマネギ抽出物(Allium Cepa)よりなる群から選択された1種以上であることを特徴とする請求項1に記載のシリコーン樹脂組成物。
- 前記f)日焼け止め剤が無機日焼け止め剤、有機日焼け止め剤及びこれらの混合物であることを特徴とする請求項1に記載のシリコーン樹脂組成物。
- 前記f)日焼け止め剤が0.1〜30重量%で含まれることを特徴とする請求項1に記載のシリコーン樹脂組成物。
- 前記g)酸化防止剤が0.1〜5重量%で含まれることを特徴とする請求項1に記載のシリコーン樹脂組成物。
- 前記h)水が0.1〜80重量%で含まれることを特徴とする請求項1に記載のシリコーン樹脂組成物。
- 前記f)保存剤が、イミダゾリジニル尿素(Imidazolidinyl Urea)、メチルパラベン(Methylparaben)、サリチル酸(Salicylic acid)、メチルクロロイソチアゾリノン(Methylchloroisothiazolinone)、メチルイソチアゾリノン(Methylisothiazolinone)、エチルパラベン(Ethylparaben)、ブチルパラベン(Butylparaben)、プロピルパラベン(Propylparaben)、イソプロピルパラベン(Isopropylparaben)、フェノキシエタノール(Phenoxyethanol)、DMDMヒダントイン(DMDM Hydantoin)、1,2−ヘキサンジオール(1,2−Hexanediol)、カプリロイルグリシン、カプリル酸グリセリル、レブリン酸ナトリウム、亜鉛グルコン酸塩、銅グルコン酸塩、亜鉛ピロリドンカルボン酸、銅ピロリドンカルボン酸、フィットスピンゴシン、フィットスピンゴシン誘導体、過酸化ベンゾイル、ピロクトンオラミン、亜鉛ピリチオン、セレン硫化物、エコナゾール、ケトコナゾール、エリスロマイシン及びクリンダマイシンよりなる群から選択された1種以上であることを特徴とする請求項1に記載のシリコーン樹脂組成物。
- A)シリコーン樹脂15〜70重量%、ワックス1〜25重量%、乳化剤2〜8重量%、及び日焼け止め剤0〜30重量%を60〜80℃で攪拌して混合する段階と、
B)前記混合された混合物に、薬物0.5〜2重量%、活性化剤1〜5重量%、酸化防止剤0〜5重量%、水0〜80重量%及び保存剤0.1〜5重量%を投入し、45〜70℃で攪拌して混合する段階と、を含み、
前記a)シリコーン樹脂が、シリコーン樹脂の合計100重量%に対して、シリコーンエラストマー10〜50重量%、フィルム形成剤2〜10重量%、シリコーン流体2〜10重量%及び環状シロキサン0〜80重量%の混合物であり、
前記フィルム形成剤は、ASTM D445、IP71に基づいて、ガラス毛細管粘度計であるウベローデ(フィッシャーサイエンティフィックカンパニー製)を用いて測定した25℃での粘度が400〜1000cstであり、
前記シリコーン流体は、
粘度1〜20cstのシリコーン流体(1)と、粘度80,000〜120,000cstのシリコーン流体(3)との混合物であり、前記シリコーン流体(1)と前記シリコーン流体(3)の重量比は、1:0.15〜0.4であり、または
粘度10,000〜15,000cstのシリコーン流体(2)と前記粘度80,000〜120,000cstのシリコーン流体(3)との混合物であり、前記シリコーン流体(2)と前記シリコーン流体(3)の重量比は、1:1.5〜2.5であり、
前記b)ワックスが、ビーズワックスまたはオリーブ油脂肪酸ソルビタンであり、
前記c)乳化剤が、セチルアルコールまたは粘度1,600〜2,000cstのシリコーン乳化剤であることを特徴とする樹脂組成物の製造方法。 - 前記B)段階は、前記薬物またはその一部と水とを50〜75℃で混合して作った混合溶液を、前記A)段階で作った混合物に先に投入して混合した後、前記活性化剤、酸化防止剤及び保存剤を投入することを特徴とする請求項9に記載のシリコーン樹脂組成物の製造方法。
- 前記混合溶液が、前記A)段階で作った混合物への投入の際に50〜75℃に維持されることを特徴とする請求項10に記載のシリコーン樹脂組成物の製造方法。
- 前記前記活性化剤、酸化防止剤及び保存剤は、前記混合溶液を、前記A)段階で作った混合物に投入した後、45〜55℃に冷却されたときに投入することを特徴とする請求項10に記載のシリコーン樹脂組成物の製造方法。
- 請求項1乃至8のいずれか一項に記載のシリコーン樹脂組成物を含むことを特徴とする瘢痕治療剤。
- 前記瘢痕治療剤がシート(sheet)タイプ、クリームタイプまたはゲルタイプであることを特徴とする請求項13に記載の瘢痕治療剤。
- 前記瘢痕治療剤は、ISO24444基準による紫外線カット指数(SPF)が25以上であることを特徴とする請求項13に記載の瘢痕治療剤。
- 前記瘢痕治療剤は、DPPH法による抗酸化効果が40%以上であることを特徴とする請求項13に記載の瘢痕治療剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0181494 | 2016-12-28 | ||
KR1020160181494A KR101921727B1 (ko) | 2016-12-28 | 2016-12-28 | 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제 |
PCT/KR2017/014888 WO2018124572A1 (ko) | 2016-12-28 | 2017-12-15 | 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020501868A JP2020501868A (ja) | 2020-01-23 |
JP6821054B2 true JP6821054B2 (ja) | 2021-01-27 |
Family
ID=62710637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019554461A Active JP6821054B2 (ja) | 2016-12-28 | 2017-12-15 | シリコーン樹脂組成物、その製造方法及びそれを含む瘢痕治療剤 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6821054B2 (ja) |
KR (1) | KR101921727B1 (ja) |
CN (1) | CN110121368A (ja) |
WO (1) | WO2018124572A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102234063B1 (ko) * | 2018-11-28 | 2021-03-31 | 주식회사 현대바이오랜드 | 흉터개선용 피복 필름 형성을 위한 이액형 겔 조성물 |
KR102285696B1 (ko) | 2019-06-13 | 2021-08-04 | 신신제약 주식회사 | 흉터 예방 또는 치료를 위한 국소용 약학적 조성물 |
CN113952502A (zh) * | 2020-07-21 | 2022-01-21 | 河南国械医疗器械有限公司 | 一种多功效硅酮凝胶敷料及其制备方法 |
KR20230136529A (ko) | 2022-03-18 | 2023-09-26 | 주식회사 다림아이앤씨 | 흉터 개선, 예방 또는 치료용 조성물 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0007140D0 (en) * | 1999-09-27 | 2000-05-17 | Dow Corning Sa | Scar treatment composition |
JP4236831B2 (ja) * | 2001-07-31 | 2009-03-11 | 花王株式会社 | 滑水性を有する化粧料 |
GB0216427D0 (en) * | 2002-07-16 | 2002-08-21 | Advanced Biotechnologies Inter | Wound dressing |
US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
JP4660171B2 (ja) * | 2004-02-05 | 2011-03-30 | 阿蘇製薬株式会社 | 救急用絆創膏 |
US20060127437A1 (en) * | 2004-12-13 | 2006-06-15 | Misty Anderson Kennedy | Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids |
ATE523210T1 (de) * | 2007-09-30 | 2011-09-15 | Meda Ab | Zusammensetzungen auf silikongelbasis zur wundheilung und narbenreduktion |
KR20100009549U (ko) * | 2009-03-20 | 2010-09-29 | (주)아모레퍼시픽 | 자외선차단용 상처치유밴드 |
US20100322875A1 (en) * | 2009-06-18 | 2010-12-23 | Advanced Bio-Technologies, Inc. | Silicone scar treatment preparation |
US20140072613A1 (en) * | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
KR102007800B1 (ko) * | 2012-11-09 | 2019-08-07 | (주)아모레퍼시픽 | 무스형의 자외선 차단용 화장료 조성물 |
KR101457789B1 (ko) * | 2013-02-13 | 2014-11-03 | 동아제약 주식회사 | 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법 |
BR112015022010A2 (pt) * | 2013-03-15 | 2017-08-29 | Juventas Therapeutics Inc | Uso de sdf-1 para mitigar a formação de cicatrizes |
US10493178B2 (en) * | 2014-07-09 | 2019-12-03 | Lubrizol Advanced Materials, Inc. | Hydrogel compositions |
CN104983585B (zh) * | 2015-06-18 | 2018-09-25 | 天津嘉氏堂科技有限公司 | 一种疤痕用防晒硅凝胶及制备方法 |
CN105012228B (zh) * | 2015-08-17 | 2018-04-20 | 郑州和济生物科技股份有限公司 | 防止疤痕形成及早期修复的玻尿酸硅凝胶组合物及制备方法 |
-
2016
- 2016-12-28 KR KR1020160181494A patent/KR101921727B1/ko active IP Right Grant
-
2017
- 2017-12-15 WO PCT/KR2017/014888 patent/WO2018124572A1/ko active Application Filing
- 2017-12-15 JP JP2019554461A patent/JP6821054B2/ja active Active
- 2017-12-15 CN CN201780081658.1A patent/CN110121368A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018124572A1 (ko) | 2018-07-05 |
KR101921727B1 (ko) | 2018-11-23 |
JP2020501868A (ja) | 2020-01-23 |
CN110121368A (zh) | 2019-08-13 |
KR20180076871A (ko) | 2018-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6821054B2 (ja) | シリコーン樹脂組成物、その製造方法及びそれを含む瘢痕治療剤 | |
JP2016222612A (ja) | 化粧料または皮膚外用剤 | |
HU230156B1 (hu) | Hagymakivonatot és zsírolajat tartalmazó szer előállítása károsodott bőrszövet, különösen sebhelyek ellátására, megelőzésére vagy kezelésére | |
JP2014114289A (ja) | 化粧料または皮膚外用剤 | |
CN108785122A (zh) | 一种祛痘共输送纳米组合物及其制备方法和应用 | |
JP2010132629A (ja) | 皮膚外用組成物 | |
JP6006101B2 (ja) | 紫外線吸収剤含有皮膚外用剤 | |
US9226890B1 (en) | Polysilicone base for scar treatment | |
EA028222B1 (ru) | Водная фотозащитная композиция для личной гигиены | |
KR20190013101A (ko) | 흉터의 예방 또는 치료를 위한 조성물 | |
JPH05186324A (ja) | 美白化粧料 | |
KR20170094747A (ko) | 고온 또는 초고온 멸균 가능한 비이온 계면활성제를 포함하는 유화 화장료 조성물 | |
JP2003128512A (ja) | 化粧料用抗菌性組成物 | |
KR102451738B1 (ko) | 다당류 점증제를 포함하는 자외선 차단용 화장료 조성물 및 이를 제조하는 방법 | |
JPS5916816A (ja) | 外用組成物 | |
KR20210096056A (ko) | 흉터 예방 또는 치료를 위한 국소용 약학적 조성물 | |
KR102587916B1 (ko) | 유기계 자외선 차단제를 포함하는 실리콘중수 타입의 화장료 조성물 | |
JP2021098655A (ja) | 皮膚外用組成物 | |
KR20160111212A (ko) | 알긴을 함유하는 수중유형 자외선 차단 화장료 조성물 | |
JP6856642B2 (ja) | 皮膚軟化組成物 | |
KR102215331B1 (ko) | 통증치료 레이저에 사용되는 통증부위 도포용 화장품 제조방법 | |
JP2003277261A (ja) | 皮膚外用剤 | |
WO2016166220A1 (en) | Composition for covering and protecting scars | |
CN113631141A (zh) | 新组合物及其用途 | |
JP2001206813A (ja) | 物理的治療用の皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200918 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201215 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6821054 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |